Celonis Appoints Daniel Brown as Chief Product Officer to Drive Platform Innovation and Growth
3.2.2025 16:38:00 CET | Business Wire | Press Release
Celonis, the global leader in Process Mining and Process Intelligence, today announced the appointment of Daniel Brown as Chief Product Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250203013107/en/
Dan Brown joins Celonis as Chief Product Officer (Photo: Business Wire)
“I am thrilled to join Celonis,” said Brown. “I’ve long admired its pioneering products, rapid innovation, and ability to deliver transformative results for customers and partners. What impresses me most is how the Celonis platform connects companies to their processes, teams to each other and AI to the business. I’m eager to contribute to this incredible journey and help shape the future of Process Intelligence.”
“Dan brings a wealth of product strategy and leadership experience to Celonis,” said Alex Rinke, co-Founder and co-CEO at Celonis. “As the market leader in Process Intelligence, we are constantly pushing the boundaries of what our platform can achieve. Dan’s proficiency at building transformative products will ensure we continue setting the benchmark for innovation and customer value as we deliver on our mission to make processes work for people, companies, and the planet.”
Brown will work closely with the Engineering, Sales, and Marketing teams to continue delivering solutions that enable companies to be more productive, more efficient, more sustainable, and get the most from game-changing technologies like AI.
Prior to joining Celonis, Brown served as Chief Product Officer at Certinia for more than six years, where he ran product management and engineering for the company's global product development organization. Before joining Certinia, Daniel spent 15 years at Microsoft where he held multiple leadership roles, including GM of Corporate Strategy and Development, GM of Dynamics AX Application R&D, and GM of Dynamics NAV R&D. Prior to that, Daniel co-founded and was VP of Product and Engineering at Netabacus, a B2B e-commerce start-up focused on small-to-medium sized businesses that was acquired by Rivio.
Brown holds multiple degrees from Stanford University, including a masters degree in computer science and an undergraduate degree in Physics.
About Celonis
Celonis makes processes work for people, companies, and the planet. The Celonis Process Intelligence Platform, powered by process mining and AI, combines process data and business context to create a living digital twin of the enterprise, connecting people to processes, teams to each other, and AI to the business. Thousands of companies worldwide, including half of the top 200 companies on the Forbes Global 2000, use Celonis to understand their business, optimize operations and drive significant value across the top, bottom, and green lines.
Celonis is headquartered in Munich, Germany, and New York City, USA, with more than 20 offices worldwide.
© 2025 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203013107/en/
Contacts
Media Contact
press@celonis.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release First Quarter 2026 Results on May 5, 202614.4.2026 22:15:00 CEST | Press Release
IFF (NYSE: IFF) today announced that it will release its first quarter 2026 earnings results following the market close on Tuesday, May 5, 2026. The management team will host a live webcast on Wednesday, May 6, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.business
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,
The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom